COMMUNIQUÉS West-GlobeNewswire

Adventist Health Promotes Joe Reppert as Chief Financial Officer
20/12/2017
ROSEVILLE, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Adventist Health —a non-profit integrated health system serving more than 75 communities on the West Coast and in Hawaii—is proud to announce the recent promotion of [...]
ALK – Financial calendar for the 2018 financial year
20/12/2017
Copenhagen, 2017-12-20 11:06 CET (GLOBE NEWSWIRE) -- 2018 financial calendar for ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ): Silent period 9 January 2018 Annual report 2017 6 February 2018 Annual General Meeting to be [...]
NeuroSearch – financial calendar for 2018
20/12/2017
Announcement no. 9-17 Page 1 of 1 Announcement 20 December 2017 NeuroSearch A/S (NEUR) hereby announces the company’s financial calendar for 2018. 9 February 2018 Annual Report 2017 25 April 2018 Annual General Meeting [...]
TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform
20/12/2017
PRESS RELEASE TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform Leuven (BELGIUM) - December 20, 2017, 7:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG) ("TiGenix" or " [...]
TiGenix confirme l'orientation stratégique du Cx601 et de la plateforme de cellules souches dérivées de tissus adipeux (eASC)
20/12/2017
COMMUNIQUÉ DE PRESSE TiGenix confirme l'orientation stratégique du Cx601 et de la plateforme de cellules souches dérivées de tissus adipeux (eASC) Louvain (BELGIQUE) - 20 décembre 2017, 07h. CET - TiGenix NV (Euronext [...]
MPX Bioceutical Corporation Provides Update on Private Placement
20/12/2017
TORONTO, Dec. 19, 2017 (GLOBE NEWSWIRE) -- MPX Bioceutical Corp. (the “ Company ” or “ MPX ”) (CSE:MPX) (OTC:MPXEF) is pleased to provide this corporate update concerning its previously announced brokered private [...]
Skyline Medical Acquiring up to 25% Equity Stake in Helomics Corporation, a Precision Diagnostics Company
19/12/2017
MINNEAPOLIS, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Skyline Medical Inc . (NASDAQ: SKLN ) (“Skyline” or the “Company”), producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, [...]
Catalyst Biosciences Announces Proposed Public Offering of Common Stock
19/12/2017
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO ), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology [...]
ProPhase Labs, Inc. Announces Preliminary Results of Its Tender Offer
19/12/2017
DOYLESTOWN, Pa., Dec. 19, 2017 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH ) ( www.ProPhaseLabs.com ), a diversified natural health medical science company (“ProPhase”), announced today the preliminary results [...]
Galectin Therapeutics Announces $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Into 2019
19/12/2017
NORCROSS, Ga., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins, today announced it entered into a $10 million unsecured [...]
Five Prime Therapeutics and Zai Lab Announce Exclusive License Agreement for FPA144 Anti-FGFR2b Antibody in Greater China and Global Strategic Development Collaboration
19/12/2017
SOUTH SAN FRANCISCO, Calif. and SHANGHAI, China, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc . (NASDAQ: FPRX ), a biotechnology company discovering and developing innovative immuno-oncology protein [...]
SDi Announces Planned Release of 2018 Global Assessment Report
19/12/2017
LOS ANGELES, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Strategic Directions International (SDi), a division of BioInformatics LLC, announced today the 2018 Global Assessment Report: The Laboratory Analytical & Life [...]
FDA Approves Spark Therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl), a One-time Gene Therapy for Patients with Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy
19/12/2017
LUXTURNA is first gene therapy for a genetic disease, first and only pharmacologic treatment for an inherited retinal disease (IRD) and first adeno-associated virus (AAV) vector gene therapy approved in U.S. Children [...]
Qu Biologics invited to present research data at inaugural Crohn’s and Colitis Congress
19/12/2017
VANCOUVER, British Columbia, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore [...]
APHL Announces Newborn Screening Funding Recipients
19/12/2017
Silver Spring, MD, Dec. 19, 2017 (GLOBE NEWSWIRE) -- For Immediate Release The Association of Public Health Laboratories (APHL) is pleased to announce the recipients of the second round of New Disorders Implementation [...]
U.S. Food and Drug Administration Approves Prior Approval Supplement for Commercial Launch of Portola Pharmaceuticals’ Novel Oral Anticoagulant Bevyxxa® (betrixaban)
19/12/2017
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA ) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Prior Approval [...]
Apellis Pharmaceuticals Expands Management Team, Appoints Timothy Sullivan Chief Financial Officer
19/12/2017
CRESTWOOD, Ky. and CAMBRIDGE, Mass., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc., (Nasdaq: APLS ) a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for [...]
TOMI Environmental Solutions, Inc. Expands Presence in the United Kingdom With New Distribution Agreement
19/12/2017
BEVERLY HILLS, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (“TOMI”) (OTCQX:TOMZ), a global decontamination company that specializes in disinfection/decontamination sales and services, [...]
Asklepion Pharmaceuticals Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Program of Intravenous Citrulline
19/12/2017
BALTIMORE, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Asklepion Pharmaceuticals, LLC (“Asklepion” or “the Company”) announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special [...]

Pages